MD, PHD
HEAD OF THE PHASE I UNIT, UNIVERSITY HOSPITAL RECHTS DER ISAR,
TECHNICAL UNIVERSITY OF MUNICH, GERMANY
About Our Speaker
Real-world evidence highlights the importance of 3L- and 4L- treatment selection to improve mCRC patients outcomes.
Sequential treatment strategy in mGC and optimization of patients outcomes in 3L and beyond.
Sequential treatment strategy in mGC and optimization of patients outcomes in 3L.